You can buy Vecladox at the lowest price in the online pharmacy Nextgen.ooo . Venetoclax is a BCL-2 inhibitor used to treat chronic lymphocytic leukemia, small lymphocytic lymphoma, or acute myeloid leukemia. Venetoclax was initially approved by the FDA in April 2016. BCL-2 family proteins are important regulators of the apoptotic process. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphomas. CLL is the most common leukemia diagnosed in Western countries. Venetoclax was developed by reverse engineering the BCL-2 protein family inhibitor navitoclax. Venetoclax is approximately 10 times more potent than navitoclax in inducing apoptosis in CLL cells. In 2018, a new indication was approved for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with or without 17p deletion who have received at least one prior therapy label. Previously, this drug was only indicated for patients with 17p gene deletion.
 
BCL-2 family proteins are essential regulators of the apoptotic process. This family includes pro-apoptotic and survival proteins for various cells. Cancer cells avoid apoptosis by suppressing programmed cell death. Selective inhibition of BCL-2 with venetoclax, while preserving BCL-xL, provides therapeutic induction of apoptosis without the negative effect of thrombocytopenia. Venetoclax helps restore the apoptotic process by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins, which leads to permeability of the outer mitochondrial membrane and activation of caspase enzymes. In preclinical studies, venetoclax has shown cytotoxic activity in tumor cells that overexpress BCL-2.